Neoplasms by Site Recruiting Phase 2 Trials for Olaparib (DB09074)

IndicationStatusPhase
DBCOND0030096 (Neoplasms by Site)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04566952Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian CancerTreatment